Related Experiment Video
Updated: Feb 5, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin
Assaf Arie Barg1,2, Sarina Levy-Mendelovich1,2, Einat Avishai2
1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis.
Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Electric Generator: Alternator
The magnetic flux passing through the coil varies sinusoidally as the loop rotates inside the magnetic field. This...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

